Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1970 Aug;39(4):657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle

B N Singh, E M Vaughan Williams
PMCID: PMC1702721  PMID: 5485142

Abstract

1. Amiodarone (2-butyl, 3-(4-diethylaminoethoxy, 3,5-diiodo, benzoyl) benzofuran hydrochloride), an anti-anginal drug which causes coronary dilatation and depresses myocardial oxygen consumption, was found to protect anaesthetized guinea-pigs against ouabain-induced ventricular fibrillation.

2. A 5% (73·4 mM) solution of amiodarone had no local anaesthetic action on guinea-pig skin.

3. Amiodarone, 20 mg/kg (29·4 μmol/kg) given daily for 6 weeks intraperitoneally, had no effect on the resting potential or action potential height, and only a small effect on the maximum rate of depolarization, of isolated rabbit atrial or ventricular muscle fibres as shown by intracellular recording. It caused a considerable prolongation of the action potential in both tissues.

4. Simultaneous administration of thyroxine (5 μg; 6·26 nmol), given daily for 3 weeks intraperitoneally, prevented the prolongation by amiodarone of the duration of the action potential.

5. Treatment of rabbits with 20 mg/kg of amiodarone daily intraperitoneally for 6 weeks had no effect on the weight of the thyroid gland, but was associated with a reduction in body growth rate.

6. Treatment of rabbits with 10 mg/kg (60·3 μmol/kg) of potassium iodide (equal in its iodine content to that of 20 mg/kg of amiodarone), given daily for 6 weeks intraperitoneally, had no effect on body growth rate or the duration of cardiac action potentials.

7. It was concluded that amiodarone had effects on cardiac action potentials similar to those which occur after thyroidectomy.

Full text

PDF
657

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BROWN-GRANT K. A comparison of thyroxine and triiodothyronine as inhibitors of pituitary thyrothrophic hormone secretion in the rabbit. J Physiol. 1955 Feb 28;127(2):352–357. doi: 10.1113/jphysiol.1955.sp005262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barzin J., Fréson A. Essais cliniques de l'aminodarone dans les affections coronariennes. Brux Med. 1969 Feb;49(2):105–122. [PubMed] [Google Scholar]
  3. Broeckhuysen J., Deltour G., Ghislain M. Some biochemical effects of amiodarone. Arzneimittelforschung. 1969 Nov;19(11):1850–1853. [PubMed] [Google Scholar]
  4. Broekhuysen J., Laruel R., Sion R. Recherches dans la série des benzofurannes. XXXVII. Etude comparée du transit et du métabolisme de l'amiodarone chez diverses espèces animales et chez l'homme. Arch Int Pharmacodyn Ther. 1969 Feb;177(2):340–359. [PubMed] [Google Scholar]
  5. Brown-Grant K., Tata J. R. The distribution and metabolism of thyroxine and 3:5:3'-triiodothyronine in the rabbit. J Physiol. 1961 Jun;157(1):157–176. doi: 10.1113/jphysiol.1961.sp006712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Charlier R., Delaunois G., Bauthier J., Deltour G. Recherches dans la série des benzofuranes. XL. Propriétés antiarythmiques de l'amiodarone. Cardiologia. 1969;54(2):83–90. [PubMed] [Google Scholar]
  7. Charlier R., Deltour G., Baudine A., Chaillet F. Pharmacology of amiodarone, and anti-anginal drug with a new biological profile. Arzneimittelforschung. 1968 Nov;18(11):1408–1417. [PubMed] [Google Scholar]
  8. Deleixhe A., Delrée G. A propos d'une nouvelle substance anti-angineuse: l'amiodarone. Rev Med Liege. 1969 May 1;24(9):377–380. [PubMed] [Google Scholar]
  9. Dohadwalla A. N., Freedberg A. S., Vaughan Williams E. M. The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias. Br J Pharmacol. 1969 Jun;36(2):257–267. doi: 10.1111/j.1476-5381.1969.tb09503.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Freedberg A. S., Papp J. G., Williams E. M. The effect of altered thyroid state on atrial intracellular potentials. J Physiol. 1970 Apr;207(2):357–369. doi: 10.1113/jphysiol.1970.sp009066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. GILL E. W., WILLIAMS E. M. LOCAL ANAESTHETIC ACTIVITY OF THE BETA-RECEPTOR ANTAGONIST, PRONETHALOL. Nature. 1964 Jan 11;201:199–199. doi: 10.1038/201199a0. [DOI] [PubMed] [Google Scholar]
  12. Hueber E. F., Kotzaurek R. Uber ein neues Mittel zur Behandlung der Angina pectoris, Amiodaron. Wien Med Wochenschr. 1968 Jul 27;118(30):657–659. [PubMed] [Google Scholar]
  13. Jouve A., Medvedowsky J. L., Benyamine R. Etude clinique de l'amiodarone. Ann Cardiol Angeiol (Paris) 1969 Jan-Mar;18(1):65–70. [PubMed] [Google Scholar]
  14. MORALES AGUILERA A., VAUGHANWILLIAMS E. M. THE EFFECTS ON CARDIAC MUSCLE OF BETA-RECEPTOR ANTAGONISTS IN RELATION TO THEIR ACTIVITY AS LOCAL ANAESTHETICS. Br J Pharmacol Chemother. 1965 Apr;24:332–338. doi: 10.1111/j.1476-5381.1965.tb01719.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Papp J. G., Vaughan Williams E. M. The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity. Br J Pharmacol. 1969 Oct;37(2):380–390. [PMC free article] [PubMed] [Google Scholar]
  16. Papp J. G., Vaughan Williams E. M. The effect of some catecholamine beta-receptor blocking compounds on the toxicity to the heart of ouabain. Br J Pharmacol. 1969 May;36(1):178P–179P. [PMC free article] [PubMed] [Google Scholar]
  17. Papp J. G., Williams E. M. A comparison of the anti-arrhythmic actions of I.C.I. 50172 and (--)-propranolol and their effects on intracellular cardiac action potentials and other features of cardiac function. Br J Pharmacol. 1969 Oct;37(2):391–399. doi: 10.1111/j.1476-5381.1969.tb10576.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Szekeres L., Williams E. M. Antifibrillatory action. J Physiol. 1962 Mar;160(3):470–482. doi: 10.1113/jphysiol.1962.sp006860. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES